Reuters -- British drugmaker GlaxoSmithKline (GSK.L) said on Monday it was starting two global late stage trials of drugs in advanced or metastatic melanoma in patients whose tumours have a particular gene mutation.
Reuters -- British drugmaker GlaxoSmithKline (GSK.L) said on Monday it was starting two global late stage trials of drugs in advanced or metastatic melanoma in patients whose tumours have a particular gene mutation.